A5084857809- Cancer Genomics and Diagnostics
- Histiocytic Disorders and Treatments
- Genetic factors in colorectal cancer
- MicroRNA in disease regulation
- Eosinophilic Disorders and Syndromes
- Mast cells and histamine
- Lung Cancer Treatments and Mutations
- Chromatin Remodeling and Cancer
- Extracellular vesicles in disease
- Computational Drug Discovery Methods
- Chronic Myeloid Leukemia Treatments
- Genomic variations and chromosomal abnormalities
- Genetics, Bioinformatics, and Biomedical Research
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Testicular diseases and treatments
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- RNA regulation and disease
- Circular RNAs in diseases
- Cancer-related molecular mechanisms research
- T-cell and Retrovirus Studies
- Curcumin's Biomedical Applications
- Nuclear Receptors and Signaling
- Gastrointestinal disorders and treatments
Assuta Medical Center
2016-2025
Ariel University
2018-2025
Tel Aviv University
2010-2015
MicroRNAs (miRNAs) are short non-coding regulatory RNAs that control gene expression and play an important role in cancer development progression. However, little is known about the of miRNAs chronic myeloid leukemia (CML). Our objective to decipher a miRNA signature associated with CML determine potential target genes signaling pathways affected by these miRNAs.Using microarrays real-time PCR we characterized profile cell lines patients reference non-CML healthy blood. Of all tested,...
Summary Histiocytic neoplasms are diverse clonal haematopoietic disorders, and clinical disease is mediated by tumorous infiltration as well uncontrolled systemic inflammation. Individual subtypes include Langerhans cell histiocytosis (LCH), Rosai–Dorfman–Destombes (RDD) Erdheim–Chester (ECD), these have been characterized with respect to phenotypes, driver mutations treatment paradigms. Less known about patients mixed histiocytic (MXH), that two or more coexisting disorders. This...
Modifying existing drugs to enhance their activity and reduce toxicity is a major focus of drug development. We developed novel class dual-action chimeric molecules for cancer therapy, linking known DNA-methylating monomethyl triazene moiety (azene) via nucleophilic substitution. In-vitro screening these chimeras on various leukemia cell lines identified potent chimera, doxorubizen, sequel the DNA intercalator topoisomerase 2 (Topo-II) inhibitor doxorubicin (Dox) azene. Molecular docking...
Abstract Background Erdheim–Chester disease (ECD), a rare inflammatory myeloid neoplasm, is known to be fundamentally reliant on the constitutive activation of MAPK signaling pathway in majority patients. Consequently, inhibition V600E-mutant BRAF kinase has proven safe and efficacious long-term therapeutic strategy for BRAF-mutant ECD Nevertheless, subset patients with CNS disease, efficacy treatment may diminish, facilitating suboptimal responses or progression. Methods We retrospectively...
p63 is a member of the p53 transcription factor family. expressed from two promoters resulting in proteins with opposite functions: transcriptionally active TAp63 and dominant-negative DeltaNp63. Similar to p53, isoforms induce cell cycle arrest apoptosis. The DeltaNp63 are variants opposing activities TAp73. To avoid unnecessary death accompanied by proper response stress, expression family members must be tightly regulated. NAD(P)H quinone oxidoreductase (NQO1) has recently been shown...
// Oshrat Hershkovitz-Rokah 1, 2, 3, * , Polina Geva Mali Salmon-Divon 1 Ofer Shpilberg 4 and Stella Liberman-Aronov Department of Molecular Biology, Faculty Natural Sciences, Ariel University, Ariel, Israel 2 Translational Research Laboratory, Assuta Medical Centers, Tel Aviv, 3 Institude Hematology, Pre-Medicine Department, School Health These authors have contributed equally to this work Correspondence to: Liberman-Aronov, email: stellar@ariel.ac.il Keywords: miRNA signature; DLBCL; FL;...
Langerhans cell histiocytosis (LCH) is an inflammatory myeloid neoplasm characterized by the accumulation of clonal mononuclear phagocyte system cells expressing CD1a and CD207. In past decade, molecular profiling LCH as well other histiocytic neoplasms demonstrated that these diseases are driven MAPK activating alterations, with somatic BRAFV600E mutations in >50% patients LCH, clinical inhibition signaling has remarkable efficacy. At same time, alterations kinase-encoding genes, such...
Erdheim-Chester disease (ECD) is characterized by excessive production and accumulation of histiocytes within multiple tissues organs. ECD patients harbor recurrent mutations genes associated with the RAS/RAF/MEK/ERK signaling pathway, particularly, BRAFV600E mutation. Following our previous finding that miR-15a-5p most prominently downregulated microRNA in compared to healthy individuals, we elucidated its role pathogenesis. Bioinformatics analysis followed a luciferase assay showed...
Abstract Background Noncoding RNAs such as microRNAs (miRNAs) have attracted attention biological pathway regulators, which differ from chromosomal translocations and gene point mutations. Their involvement in the molecular mechanisms underlying light chain (AL) amyloidosis pathogenesis is yet to be elucidated. Aims To decipher specific miRNA expression profile AL‐amyloidosis examine how miRNAs are involved AL pathogenesis. Methods The of mRNA bone marrow (BM)‐derived CD138+ cells were...
The pathogenesis of histiocytic neoplasms is driven by mutations activating the MAPK/ERK pathway, but little known about transcriptional and post-transcriptional alterations involved in these neoplasms. We analyzed microRNA (miRNA) expression plasma samples tissue biopsies Erdheim–Chester disease (ECD) Langerhans cell histiocytosis (LCH) patients. In silico analysis revealed a potential role miRNAs regulating gene as compared with healthy controls (HC). NanoString 101 differentially...
The efficient synthesis of molecular hybrids including a DNA-intercalating 9-anilinoacridine (9-AnA) core and methyl triazene DNA-methylating moiety is described. Nucleophilic aromatic substitution (SN Ar) electrophilic (EAS) reactions using readily accessible starting materials provide quick entry to novel bifunctional anticancer molecules. chimeras were evaluated for their activity. Chimera 7b presented the highest antitumor activity at low micromolar IC50 values in antiproliferative...
Background: Scientists have extensively investigated curcumin, yielding many publications on treatments of cancer. Numerous derivatives curcumin were synthesized, evaluated for their anti-oxidant and free-radical scavenging, SAR, ADME properties tested in anticancer applications. Objective: We decided to exploit as a bioactive core platform carrying drugs, which likely possesses carboxyl moiety potential linkage the carrier drug delivery. Methods: The goal this work is develop biolabile...